Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 04 Dec 2023 for Niagen Bioscience, Inc., €6,473.
Filing timeline
BuySaleBrianna Gerber
Insider track record
Disclosed buys
1
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
1
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +426.6%Entry US$1.43 · Close at T+365 US$7.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Brianna Gerber: trading record in brief
Brianna Gerber discloses dealings in Niagen Bioscience, Inc. to SEC (Form 4). Between 12 August 2023 and 1 December 2023, the trades on record add up to 2 filings.
No open-market sale appears; the market trades are 1 purchase worth €6,473. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 option exercise.
The latest filing, published on 4 December 2023, reports an open-market purchase of €6,473 in Niagen Bioscience, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Brianna Gerber
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
5,000 shares@ US$1.41100.0% of flowCommon StockSEC:0001628280-23-040625:0
Canonical exit: 29 Feb 2024 (T+90)
22,436 sharesCommon StockSEC:0001628280-23-029599:0
2 of 2 declarations
